All companies
Visit website
TRIAGENICS
OperatingTriAgenics, Inc.
Healthcare · Founded 2013
Eliminating wisdom teeth extractions with a non-surgical procedure
Post-money valuation ⓘ
$38.9M
As of Nov 2024 · from TriAgenics Preferred Stock 1 · pre-money + amount raised, not a traded price
Total raised
$4,913,921
Across 2 rounds since 2023
Latest share price
$3.00
TriAgenics Preferred Stock 1 offering price
Financials
FY2021–FY2025 · from SEC filings · hover any figure for its source$0
−$1.1M
2021
$0
−$1.4M
2022
$0
−$1.4M
2023
$0
−$2.2M
2024
$0
−$2.2M
2025
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2021
FY2022
FY2023
FY2024
FY2025
Income statement
Revenue
$0
$0
$0
$0
$0
Cost of goods sold
$563,628
$0
$0
$0
$0
Net income
-$1,062,543
-$1,433,220
-$1,442,937
-$2,183,070
-$2,242,946
Taxes paid
$3,376
$3,442
$1,590
$2,433
-$410
Balance sheet
Cash
$2,793,870
$1,458,412
$722,537
$976,252
$3,045,890
Accounts receivable
$0
$0
$0
$0
$0
Total assets
$2,980,140
$1,570,161
$791,832
$1,290,005
$3,246,152
Short-term debt
$47,364
$85,782
$26,472
$159,014
$160,614
Long-term debt
$4,476
$2,524
$0
$0
$0
Total liabilities
$51,840
$88,306
$26,472
$159,014
$160,614
Other
Headcount
—
2
2
2
3
Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited; no pill means the filing didn’t state one. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Post-money = pre-money + amount raised · caps marked$38.9M
post-money
TriAgenics Preferred Stock 1
A dashed amber step is a SAFE/note valuation cap — a conversion ceiling agreed for that instrument, not a priced valuation of the company. Steps are not comparable across bases.
Fundraising history
Raised $0 / $3M
Raised $4.9M / $5MInvestors 1,584Post-money $38.9M
Reg CF annual-report compliance
Not required3+ reports filed & assets ≤ $10M
Filed 3 of 3 annual reports (FY2023–FY2025)
1,584 investors
holder-count proxy
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
View all 19 filings on EDGARSource: ManualCIK 0001732710Share price $3.00
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.